• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Reviewing IDS 2023 and Psoriasis Clinical Cases With Tristan Hasbargen, PA-C

News
Article

Hasbargen presented clinical cases alongside James Del Rosso, DO, at IDS 2023.

At the 2023 Inflammatory Disease Summit in Las Vegas, Nevada, Tristan Hasbargen, PA-C, presented during rotating breakout sessions related to psoriatic arthritis, psoriasis, hidradenitis suppurativa, and atopic dermatitis. Hasbargen, a board-certified physician assistant at Dermatology Associates of Tallahassee and the journal and education chair for Diversity in Dermatology, delved into psoriasis clinical cases alongside James Del Rosso, DO.

“There are many ways you can treat these patients. But we just wanted other opinions so that other people may think differently and also hear different insights from their peers and really engage the audience in that way,” said Hasbargen.

Transcript

Tristan Hasbargen, PA-C: My name is Tristan Hasbargen and I'm a PA. I've been practicing for 11 years in Tallahassee, Florida. I am the education and journal chair of the Diversity in Dermatology organization.

Dermatology Times: Can you please give an overview of the breakout sessions at IDS 2023 and your psoriasis presentation?

Hasbargen: Today we had 4 breakout sessions at the Inflammatory Disease Summit in the afternoon, where we talked about psoriatic arthritis in one workshop, we did deroofing for the treatment of HS. We did clinical cases of psoriasis that Dr. Del Rosso and I presented, and then there was the atopic dermatitis, clinical cases. So Dr. Del Rosso and I wanted to come up with cases that would really stimulate the way we think as providers. Not all of our patients are cut and dry. And so we wanted to make some complex cases with adding in hepatitis C or different comorbid conditions that you have to consider for the treatment of psoriasis and really engage them and challenge them and what their answers and reasoning why. There are many ways you can treat these patients. But we just wanted other opinions so that other people may think differently and also hear different insights from their peers and really engage the audience that way.

Dermatology Times: What did you enjoy about the first-ever Inflammatory Disease Summit?

Hasbargen: This has been a phenomenal conference. I liked that there were both the didactic and the breakout sessions. I think they did it really well where you're not stuck in a classroom the whole time and so you can engage more with your peers. I think Lauren has done a phenomenal job in choosing her faculties. I really enjoyed listening to Joslyn Kirby on treating HS and Andrea Nguyen did a phenomenal job in the details of the clinical trials, which is something that I think needs to be addressed more often. We are immersed in evaluating data, but some of us are not as strong in that realm. So really kind of understanding how clinical trials work is just really, really good. I'm really just excited about the direction of the Inflammatory Disease Summit. We got a lot of great feedback, and I'm just really excited to see where it'll go next year, but I know we're going to have a lot of great things.

[Transcript edited for clarity]

Related Videos
© 2024 MJH Life Sciences

All rights reserved.